Aims: Hepatitis C virus (HCV) infection is a global important health issue affecting around 150-170 million patients around the world, around 1-1.3% of the Libyan population are affected by HCV. HCV genotyping plays an important role in the clinical decision and epidemiological studies; there are six major genotypes worldwide. The aim of the study was to establish the local genotypic profile and characterize the associated treatment response rate for patients on pegylated interferon and ribavirin in Tripoli Center Hosptial (TCH) Tripoli, Libya. Methods: A total of 72 patients with a measurable serum HCV-RNA were enrolled between 2014 and 2015. HCV Genotyping was performed by the Abbott Real-Time HCV assay v2.0 using Applied Biosystem Real-Time PCR. Results: HCV with genotype 4 forms the highest incidence rate of infection, presented with 41.6%, followed by 1a (9.7%), 2 (9.7%) and 1b (6.9%). While other HCV genotype 1 and genotype 3 subtypes were detected in (27.7%). The HCV genotype 1b had achieved SVR with higher rate representing 100% of the treatment more than that of the HCV genotype 1a that displayed 28%. In contrast, the HCV genotype 3a infected patients had succeeded to achieve the SVR (100%) than other HCV genotype 3 subtypes. However, HCV genotype 2 have fully achieved the ETR with a rate of 100%. Conclusions: The sustained virological response rate with different HCV genotypes was indeed 92%, 73%, 57% and 50% of patients infected with HCV genotypes 3, 4, 2 and 1 respectively. This would reflect that the screening for HCV genotyping predicting the treatment response. Nevertheless, the HCV genotype 1a displayed the minimum level of the SVR. These results were consistent with previous reports.